Dr. Heron specializes in stereotactic radiosurgery (SRS), stereotactic ablative radiotherapy (SABR), high-dose rate brachytherapy, intensity-modulated radiation therapy (IMRT), intraoperative radiotherapy, and interstitial hyperthermia. Dr. Heron has been a thought leader in advanced radiation therapy techniques and innovative use of radiosurgery in central nervous system, recurrent head & neck, prostate and pancreatic cancers.
Dr. Mantica specializes in the treatment of adult high grade gliomas, central nervous system lymphoma, and neurological complications of cancer treatment. Her translational research interests include women’s neuro-oncology, metastatic brain disease and high grade gliomas.
Dr. Edward Chu is involved in basic, clinical, and translational cancer research. His basic research interests are focused on the characterization of molecular mechanisms underlying the development of cellular drug resistance, especially as it relates to the fluoropyrimidine class of anticancer agents. His research group was the first to identify translational autoregulation as a novel regulatory mechanism in eukaryotes for controlling the expression of the folate-dependent enzymes, thymidylate synthase and dihydrofolate reductase. His clinical/translational research efforts focus on identifying novel drugs and treatment strategies for colorectal cancer and other GI cancers and in developing early phase clinical trials. He has a strong interest in integrating Chinese herbal medicine with standard cancer chemotherapy, with the goal of enhancing clinical activity and reducing toxicities.